MedTrace Logo

Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis

NCT00917007 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-10-25

No results posted yet for this study

Summary

The purpose of this research study is to more accurately measure the amount of true red blood cell breakdown (hemolysis) in newborn babies with potentially problematic blood type mismatch with their mothers (ABO incompatibility), and to examine how the true level of red blood cell destruction relates to other laboratory tests obtained in newborns with jaundice.

A better understanding of the true amount of red blood cell destruction that is caused by blood type mismatch, as well as how it relates with other laboratory tests ordered for ABO incompatibility and red blood cell destruction, would help avoid unnecessary testing, treatment and prolonged hospital stays in such babies.

Conditions

  • ABO Incompatibility
  • Hemolytic Disease of Newborn
  • Neonatal Jaundice
  • Neonatal Hyperbilirubinemia

Sponsors & Collaborators

  • New York State Department of Health

    collaborator OTHER_GOV

  • Laboratory Alliance of Central New York

    collaborator UNKNOWN

  • Stanford University

    collaborator OTHER

  • State University of New York - Upstate Medical University

    lead OTHER

Principal Investigators

  • Richard H Sills, MD · SUNY Upstate Medical Univeristy

Eligibility

Max Age
28 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00917007 on ClinicalTrials.gov